Is SCHD a Good ETF to Buy?
With around $65.7 billion in net assets, Schwab’s US Dividend…
Sell
15
GLUE Quote, Financials, Valuation and Earnings
Last price:
$6.53
Seasonality move
:
0.27%
Day range:
$6.88 - $7.30
52-week range:
$3.21 - $12.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.06x
Volume:
587.1K
Avg. volume:
1.5M
1-year change:
24.71%
Market cap:
$423.3M
Revenue:
--
EPS (TTM):
-$1.83
Earnings Data
Next earnings date for GLUE
Mar 14
2025
Most recent earnings per share
-$0.29
Beat by $0.18
(Nov 7/2024)
Consensus Estimate
-$0.47
(Nov 7/2024)
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
GLUE Quarterly Earnings History
| Date | Quarter | Revenue Forecast | Actual Revenue | Reported EPS | Consensus EPS | Beat/Miss |
|---|---|---|---|---|---|---|
| 03/31/2025 | Q1 | $4.9M | -- | -- | -$0.41 | -- |
| 03/14/2025 | Q4 | $51.2M | -- | -- | $0.11 | -- |
| 11/07/2024 | Q3 | $3.2M | $9.2M | -$0.29 | -$0.47 | $0.18 |
| 08/08/2024 | Q2 | $1.3M | $4.7M | -$0.43 | -$0.54 | $0.11 |
| 05/09/2024 | Q1 | $1.4M | $1.1M | -$0.53 | -$0.58 | $0.05 |
| 03/14/2024 | Q4 | $15.1M | -- | -$0.58 | -$0.39 | -$0.19 |
| 11/09/2023 | Q3 | -- | -- | -$0.70 | -$0.74 | $0.04 |
| 08/10/2023 | Q2 | -- | -- | -$0.71 | -$0.69 | -$0.02 |
| 05/11/2023 | Q1 | -- | -- | -$0.65 | -$0.68 | $0.03 |
| 12/31/2022 | Q4 | -- | -- | -$0.63 | -$0.62 | -$0.01 |
| 11/10/2022 | Q3 | -- | -- | -$0.58 | -$0.59 | $0.01 |
| 08/11/2022 | Q2 | -- | -- | -$0.57 | -- | -- |
| 05/11/2022 | Q1 | -- | -- | -$0.51 | -- | -- |
| 02/28/2022 | Q4 | -- | -- | -$0.50 | -- | -- |
| 11/10/2021 | Q3 | -- | -- | -$0.43 | -- | -- |
| 08/12/2021 | Q2 | -- | -- | -$3.63 | -- | -- |
| 03/31/2021 | Q1 | -- | -- | -$0.29 | -- | -- |
| 12/31/2020 | Q4 | -- | -- | -$0.90 | -- | -- |
| 09/30/2020 | Q3 | -- | -- | -$0.30 | -- | -- |
| 06/30/2020 | Q2 | -- | -- | -$0.25 | -- | -- |
| 03/31/2020 | Q1 | -- | -- | -$0.20 | -- | -- |
Monte Rosa Therapeutics Earnings Questions
-
How Much did Monte Rosa Therapeutics Generate in Revenue Last Quarter?
Monte Rosa Therapeutics reported $9.2M worth of top line sales in its most recent quarter.
-
Did Monte Rosa Therapeutics Beat Earnings Last Quarter?
Monte Rosa Therapeutics announced earnings per share of -$0.29 which represents a beat of analyst forecast a -$0.47 per share.
-
Is Monte Rosa Therapeutics Profitable?
Monte Rosa Therapeutics reported -- that represents -- per share over the last quarter.
-
What is the Analyst Consensus for Monte Rosa Therapeutics EPS Next Year?
Monte Rosa Therapeutics's earnings are forecast to decrease from -$2.63 per share to -$1.11 per share next year representing a decrease of -63.83%.
-
When is Monte Rosa Therapeutics's Earnings Date?
Monte Rosa Therapeutics's next earnings date is March 14, 2025.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is NAIL a Good ETF to Buy?
If you’re thinking about buying the NAIL ETF, this article…
3 High Dividend Dow Jones Stocks
Thanks to surging stock prices over the past two years,…
Stock Ideas
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 125x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
NARI alert for Jan 7
Inari Medical [NARI] is up 22.25% over the past day.
Buy
70
PDEX alert for Jan 7
Pro-Dex [PDEX] is down 10.89% over the past day.
Buy
52
ALCO alert for Jan 7
Alico [ALCO] is down 3.89% over the past day.
